4.5 Review

Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Gastroenterology & Hepatology

Should Treatment Indications for Chronic Hepatitis B Be Expanded?

Wen-Juei Jeng et al.

Summary: Current treatment for chronic hepatitis B virus (HBV) does not eradicate the virus, requiring long-term maintenance for most patients. Expanding treatment to certain patient populations, such as immune tolerant patients and those with evidence of liver disease, is supported by available evidence. However, data supporting treatment expansion for confirmed inactive carriers and other immune tolerant patients is lacking. New therapies that can achieve HBsAg loss in a high percentage of patients after a finite course of treatment may allow for more liberal HBV treatment indications in the future.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Article Gastroenterology & Hepatology

Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy

Amir M. Mohareb et al.

Summary: This study investigated the impact of past and active hepatitis B virus (HBV) infection on immunorecovery and mortality in HIV-infected individuals initiating tenofovir-based antiretroviral therapy (ART). The findings suggest that individuals with HIV and past HBV infection, as well as those with isolated anti-HBcAb-positive serology, experience lower mortality compared to individuals with HBsAg and high HBV DNA. Therefore, additional HBV-related management may not be necessary for these individuals.

JOURNAL OF VIRAL HEPATITIS (2021)

Editorial Material Gastroenterology & Hepatology

Extending treatment eligibility for chronic hepatitis B virus infection

Anna L. McNaughton et al.

Summary: Despite efforts to support enhanced prevention, diagnosis, and treatment, progress towards hepatitis B virus (HBV) elimination targets remains slow. Drawing insights from interventions against HIV, advocating for the wider use of antiviral therapy for HBV can have potential public health benefits in preventing liver disease and reducing transmission.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Review Gastroenterology & Hepatology

Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis

Mingjuan Tan et al.

Summary: Many people with chronic HBV infection worldwide may be eligible for treatment, but the proportion of those who are actually eligible is not high. Future studies should focus more on reporting treatment eligibility in order to improve global treatment coverage.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Article Immunology

Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada

Kyle A. Thompson et al.

Summary: Initiating PrEP medications for HIV can also effectively treat HBV infection. A study of a provincial PrEP program in British Columbia revealed a 0.86% prevalence of chronic HBV among enrollees, with 46.3% lacking follow-up HBV DNA monitoring, highlighting the importance of HBV education for PrEP prescribers.

OPEN FORUM INFECTIOUS DISEASES (2021)

Article Immunology

Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP

Vita W. Jongen et al.

Summary: The study found high adherence to edPrEP among MSM, with most condomless anal sex acts being effectively protected, confirming the efficacy of edPrEP in preventing HIV acquisition. Blood sample analysis also indicated an average of two to three tablets per week being taken.

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2021)

Article Gastroenterology & Hepatology

APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients

Jia-Horng Kao et al.

Summary: Chronic HBV infection is currently incurable and long-term treatment with NAs can reduce complications, but stopping treatment may lead to virological relapse and adverse outcomes. Close monitoring and personalized follow-up strategies are essential for a safe cessation of NA therapy.

HEPATOLOGY INTERNATIONAL (2021)

Article Medicine, General & Internal

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz et al.

Summary: The study showed that injectable Cabotegravir was more effective in preventing HIV infection among MSM and transgender women compared to daily oral Tenofovir Disoproxil Fumarate-Emtricitabine. Strategies are needed to prevent INSTI resistance in cases of Cabotegravir PrEP failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Review Immunology

Health system adaptations and considerations to facilitate optimal oral pre-exposure prophylaxis scale-up in sub-Saharan Africa

Daniel K. Were et al.

Summary: PrEP has been progressively scaled up in sub-Saharan African countries as part of comprehensive HIV prevention, but slow scale-up due to unprepared health systems has resulted in suboptimal coverage among high-risk populations.

LANCET HIV (2021)

Article Immunology

HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study

Christian Laurent et al.

Summary: The study on HIV pre-exposure prophylaxis (PrEP) in men who have sex with men (MSM) in West Africa showed that PrEP could effectively prevent HIV infection without increasing risky sexual behaviors or other sexually transmitted infections. Urgent implementation of PrEP in West Africa is recommended, with special attention to retention in care and PrEP adherence to ensure its full prevention potential.

LANCET HIV (2021)

Review Gastroenterology & Hepatology

Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad

Marc G. Ghany et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

Review Gastroenterology & Hepatology

Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift

Yun-Fan Liaw

HEPATOLOGY INTERNATIONAL (2019)

Editorial Material Gastroenterology & Hepatology

Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B

Pietro Lampertico et al.

HEPATOLOGY (2018)

Article Gastroenterology & Hepatology

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault et al.

HEPATOLOGY (2018)

Article Medicine, General & Internal

Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia

Hailemichael Desalegn et al.

BMC MEDICINE (2018)

Article Gastroenterology & Hepatology

AASLD guidelines for treatment of chronic hepatitis B

Norah A. Terrault et al.

HEPATOLOGY (2016)

Article Gastroenterology & Hepatology

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

S. K. Sarin et al.

HEPATOLOGY INTERNATIONAL (2016)

Review Gastroenterology & Hepatology

Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

George Papatheodoridis et al.

HEPATOLOGY (2016)

Article Immunology

The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B

Marc M. Solomon et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)

Article Medicine, General & Internal

Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women

Jeanne M. Marrazzo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

J. -M. Molina et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Gastroenterology & Hepatology

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Sundeep Goyal et al.

INDIAN JOURNAL OF GASTROENTEROLOGY (2015)

Article Infectious Diseases

Patient preferences for hepatitis B therapy

Seng Gee Lim et al.

ANTIVIRAL THERAPY (2013)

Article Immunology

The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women

Rochelle P. Walensky et al.

CLINICAL INFECTIOUS DISEASES (2012)

Article Medicine, General & Internal

Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana

Michael C. Thigpen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

J. M. Baeten et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.

Robert M. Grant et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Gastroenterology & Hepatology

Hepatitis B and Human Immunodeficiency Virus Coinfection

Chloe L. Thio

HEPATOLOGY (2009)

Article Medicine, General & Internal

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

Patrick Marcellin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Gastroenterology & Hepatology

Risk and predictors of mortality associated with chronic hepatitis B infection

Uchenna H. Iloeje et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)